Pfizer Inc. $PFE Shares Sold by Martingale Asset Management L P

Martingale Asset Management L P decreased its stake in Pfizer Inc. (NYSE:PFE) by 6.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 474,418 shares of the biopharmaceutical company’s stock after selling 31,190 shares during the quarter. Martingale Asset Management L P’s holdings in Pfizer were worth $11,813,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of PFE. Norges Bank acquired a new stake in shares of Pfizer in the fourth quarter valued at about $1,830,986,000. Bank of New York Mellon Corp grew its position in shares of Pfizer by 38.9% in the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock valued at $1,208,023,000 after purchasing an additional 13,581,757 shares during the period. Franklin Resources Inc. raised its position in shares of Pfizer by 47.8% in the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after buying an additional 8,108,887 shares during the last quarter. Capital World Investors raised its position in shares of Pfizer by 51.5% in the fourth quarter. Capital World Investors now owns 21,433,890 shares of the biopharmaceutical company’s stock valued at $533,704,000 after buying an additional 7,287,194 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Pfizer by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after buying an additional 7,031,162 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 0.1%

Shares of PFE opened at $26.19 on Friday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The firm has a 50-day moving average price of $26.43 and a 200 day moving average price of $26.32. The firm has a market capitalization of $149.26 billion, a P/E ratio of 19.99 and a beta of 0.34.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same quarter in the prior year, the firm posted $0.92 earnings per share. Pfizer’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 12th. Shareholders of record on Friday, May 8th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date of this dividend was Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on PFE shares. Bank of America reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Pfizer in a research report on Monday, June 1st. CICC Research started coverage on shares of Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price for the company. Guggenheim increased their target price on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Finally, Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $28.82.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s new weight-loss data is being viewed as encouraging for its obesity franchise, potentially improving the competitive case for its pipeline and helping sentiment around future growth. Article Title
• Positive Sentiment: Pfizer’s expanded U.S. label for HYMPAVZI is adding to optimism around the hemophilia business by widening the addressable patient pool, which may support future specialty-drug sales. Article Title
• Positive Sentiment: RBC recently upgraded Pfizer to Sector Perform, saying the valuation has reset and the risk-reward profile looks more balanced ahead of pipeline catalysts. Article Title
• Positive Sentiment: Some recent articles argue Pfizer’s Seagen oncology platform and newly acquired obesity assets could help offset patent-expiry and post-COVID revenue pressure, supporting a long-term turnaround thesis. Article Title
• Neutral Sentiment: Analysts currently rate Pfizer around Hold on average, suggesting the market sees limited near-term upside until more pipeline and commercial execution proves out. Article Title
• Negative Sentiment: Bearish commentary continues to highlight Pfizer’s dividend yield as a sign of underlying concern about cash flow, debt, and the company’s ability to support both payouts and reinvestment. Article Title

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.